logo
Share SHARE
FONT-SIZE Plus   Neg

UK JCVI Not Recommends Novartis's Meningitis B Vaccine Bexsero For Immunization

Swiss drug maker Novartis AG (NVS), Wednesday said the UK Joint Committee on Vaccination and Immunisation or JCVI took an interim position to not recommend Bexsero vaccine for inclusion in the National Immunisation Programme, driven by evaluation based on cost-effectiveness assumptions. The company added that the JCVI does not feel that the decision is in the interest of the public.

Novartis said the JCVI made its evaluation before any pricing discussion with it and if the position is not changed, it will postpone Bexsero access.

In January 2013, the European Medicines Agency licensed Bexsero for active immunization of individuals from two months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Many apps are designed to enhance productivity, simplify social networking or provide other useful benefits. These apps are practical and functional. Others are shaping day-to-day lives. Thanks to these apps, the smartphones have already replaced the watch, calendar, calculator, address book, voice... The global app market would be worth $6.3 trillion by 2021, compared to $1.3 trillion in 2016, according to a new report from analyst firm App Annie. The expected growth in the global app market is said to reflect the significantly increasing number of smartphone owners and their use of mobile apps. Agricultural products giant Monsanto Co. on Wednesday reported a nearly 18 percent increase in profit for the third quarter from last year, reflecting strong sales growth in the agricultural productivity segment and a lower tax provision. Looking ahead, the company affirmed its outlook for fiscal 2017 ongoing earnings.
comments powered by Disqus
Follow RTT